Soft Gel Vaginal Estradiol Composition for Better Treatment Compliance
Solution Overview
Problem
Existing treatments for vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD) face compliance issues due to the form of estrogen-based pharmaceuticals, leading to incomplete or discontinued treatment, and they do not effectively address symptoms such as vaginal dryness, dyspareunia, and increased vaginal pH.
Innovation Solution
A soft gel vaginal pharmaceutical composition containing solubilized estradiol is designed for improved safety, ease of administration, and enhanced efficacy, with adjustable dosages to ensure clinical response, including manual or digital insertion and use of a suppository form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing estrogen-based pharmaceutical forms are used for VVA treatment, then estrogen therapy effectiveness is achieved, but patient compliance deteriorates due to formulation-related problems
Solution Approach 1:
The patent changes the physical and chemical parameters of the estradiol formulation by solubilizing it in specific carriers (e.g., caprylic/capric triglyceride, medium chain fatty acid esters) and adjusting the dosage form parameters (suppository, cream, or gel). This transformation improves patient compliance by making the formulation more acceptable and easier to administer while maintaining treatment effectiveness through controlled release and optimized bioavailability.
2Reliability
If conventional vaginal estradiol formulations are used, then VVA symptoms are treated, but vaginal discharge increases causing discomfort
Solution Approach 1:
The patent applies local quality by formulating estradiol with specific carriers and adjuvants that provide different properties at different locations within the vaginal tissue. The solubilized estradiol in oil-based carriers provides targeted local effect at the vaginal mucosa while minimizing systemic absorption and discharge. The formulation creates a localized therapeutic zone that treats VVA symptoms without causing excessive discharge.
Solution Approach 2:
The patent uses intermediary substances (solubilizing agents like caprylic/capric triglyceride, medium chain fatty acid esters, and co-solvents) as mediators between the estradiol and the vaginal tissue. These intermediaries facilitate controlled delivery and absorption of estradiol while minimizing harmful effects such as discharge. The intermediaries act as carriers that regulate the release and distribution of the active ingredient.
3Reliability
If estradiol dosage is increased to improve clinical response, then treatment efficacy improves, but safety concerns increase
Solution Approach 1:
The patent implements dynamics by creating a controlled-release formulation where the estradiol release rate can be adjusted based on patient response. The solubilized formulation in oil-based carriers provides sustained release over extended periods, allowing for lower total dosages compared to conventional forms. This dynamic release profile maintains therapeutic efficacy while reducing peak concentrations that would cause safety concerns.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of estradiol delivery through solubilization in specific carriers and adjustment of formulation composition. By optimizing the carrier type, concentration, and release characteristics, the formulation achieves improved clinical response at lower dosages. The parameter optimization balances efficacy and safety by controlling the rate and extent of estradiol absorption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The soft gel vaginal composition provides effective treatment for VVA and FSD by improving patient compliance, reducing vaginal discharge, and enhancing clinical parameters like vaginal pH, superficial cell percentage, and dyspareunia severity, with adjustable dosages for personalized treatment.
Implementation Method 1
a dosage form comprising the estradiol is manually or digitally inserted
Implementation Method 2
The soft gel vaginal pharmaceutical composition eases vaginal administration, provides improved safety of insertion, minimizes vaginal discharge following administration, and provides a more effective dosage form having improved efficacy
Data Source
AI summary
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).



